AstraZeneca Cash Flow Statement
NYSE: AZNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AstraZeneca free cash flow
In fiscal 2025, AstraZeneca generated $14.57 billion of operating cash flow and spent $2.81 billion on capital expenditures. That left free cash flow of $11.77 billion, a free-cash-flow margin of 20.0% of revenue. Free cash flow was up 18.4% from the prior year's $9.94 billion.
AstraZeneca returned $5.49 billion to shareholders: $4.97 billion in dividends and $521.0 million in share repurchases, equal to 47% of free cash flow. Free cash flow covered dividend payments 2.4 times.
Summary generated from market data by MetaCap's automated system. Methodology
AstraZeneca cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 10.23B | 7.04B | 5.96B | 3.29B | 115.00M | 3.14B | 1.23B | 2.05B | 2.87B | 3.41B |
| Net Income growth (YoY) | +45.33% | +18.12% | +81.02% | +2763.48% | -96.34% | +156.23% | -40.15% | -28.52% | -15.80% | +20.52% |
| Stock-Based Compensation | 719.00M | 660.00M | 579.00M | 619.00M | 615.00M | 277.00M | 259.00M | 219.00M | 220.00M | 241.00M |
| Operating Cash Flow | 14.57B | 11.86B | 10.35B | 9.81B | 5.96B | 4.80B | 2.97B | 2.62B | 3.58B | 4.14B |
| Capital Expenditures | -2.81B | -1.92B | -1.36B | -1.09B | -1.09B | -961.00M | -979.00M | -1.04B | -1.33B | -1.45B |
| Investing Cash Flow | -6.81B | -7.98B | -4.06B | -2.96B | -11.06B | -285.00M | -657.00M | 963.00M | -2.33B | -3.97B |
| Dividends Paid | -4.97B | -4.63B | -4.48B | -4.36B | -3.86B | -3.57B | -3.59B | -3.48B | -3.52B | -3.56B |
| Share Repurchases | -521.00M | -81.00M | — | — | -149.00M | — | — | — | — | — |
| Debt Issued | 15.00M | 6.49B | 3.82B | — | 12.93B | 2.97B | 500.00M | 2.97B | 1.99B | 2.49B |
| Debt Repaid | -2.03B | -4.65B | -4.94B | -1.27B | -4.76B | -1.61B | -1.50B | -1.40B | -1.75B | — |
| Financing Cash Flow | -7.54B | -4.00B | -6.57B | -6.82B | 3.65B | -2.20B | -1.76B | -2.04B | -2.94B | -1.32B |
| Free Cash Flow | 11.77B | 9.94B | 8.98B | 8.72B | 4.87B | 3.84B | 1.99B | 1.57B | 2.25B | 2.70B |
This table shows 10 annual periods of AstraZeneca's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, stock-based compensation, operating cash flow. Values in USD; B = billions, M = millions. Fiscal periods follow AZN's reporting calendar. What is a cash flow statement?